Allarity Therapeutics, Inc. · NASDAQ:ALLR
Allarity Therapeutics — Investor Presentation (May 2026)
22 slides from Allarity Therapeutics's investor presentation, May 8, 2026
Slide 1: Dual inhibition of PARP and WNT: A novel drug-biomarker combination in clinical trials
Copyright © 2023 Allarity Therapeutics. All rights reserved. Nasdaq: ALLR Dual inhibition of PARP and WNT: A novel drug - biomarker combination in clinical trials Thomas Jensen, CEO
Slide 2: Legal Statement
2 Allarity Therapeutics Legal Statement This presentation is provided for informational purposes only and is subject to change. This presentation is furnished as Exh ibi t 99.1 to the Company’s Current Report on Form 8 - K pursuant to Item 7.01. The information in this presentation shall not be deem
Slide 3: A Unique Approach to Advancing a Unique Cancer Therapy
3 Allarity Therapeutics Corporate Overview Allarity Therapeutics: A Unique Approach to Advancing a Unique Cancer Therapy » Allarity was founded on its proprietary gene expression technology - the Drug Response Predictor (DRP) o DRPs have successfully been developed for dozens of individual cancer dr
Slide 4: Our DRP Companion Diagnostics Platform
Our DRP ® Companion Diagnostics Platform
Slide 5: The DRP Platform Addresses the Complexity of Cancer
5 In vitro TRANSCRIPT -OMICS HUMAN SYSTEMS BIOLOGY In vitro Drug Response DATA Multi Gene DRP DRUG BLIND CLINICAL VALIDATION 14 The DRP ® P latform Addresses the Complexity of Cancer Cancer is Very Complex “Systems biology” is used to analyze all genes (~25,000) expressed in a cancer cell/tumor, wit
Slide 6: DRP CDx: Predicting a Cancer Patient's Drug Response
6 Compare patients’ tumor gene expression to DRP ® signature Allarity Therapeutics DRP ® CDx: Predicting a Cancer Patient’s Drug Response Identify patients with high DRP ® score for a given drug STRONG WEAK Patients’ biopsy samples Step 1 Step 2 Step 3 WEAK MODERATE STRONG PATIENTS’ TUMORS DRP + PAT
Slide 7: Results of LiPlaCis Phase II Trial
7 PR SD24w+ SD24w− PD 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 Results of LiPlaCis Phase II Trial Best overall response D R P p r e d i c t e d L i P l a C i s s e n s i t i v i t y PR SD24w+ SD24w− PD 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 CC=0.40, P=0.007 Allarity Therapeutics . * Nielsen et al: Predictive biomarker
Slide 8: Revitalizing Former Big Pharma Therapeutics with Our DRP CDx
8 Allarity Therapeutics Revitalizing Former Big Pharma Therapeutics with Our DRP ® CDx Companion Diagnostics Low Average Patient Benefit High Average Patient Benefit Classical Drug Development Treat all of the patients Allarity Approach Treat only patients sensitive to therapy RIGHTS INDICATION PHAS
Slide 9: Ongoing Phase Clinical trials: Stenoparib monotherapy and combination with Temozolomide
Ongoing Phase 2 Clinical trials: Stenoparib monotherapy in recurrent Platinum Resistant Ovarian cancer as well as Relapsed Small Cell Lung Cancer in combination with Temozolomide
Slide 10: First-in-class small molecule inhibitor of PARP with dual Tankyrase activity
10 • First - in - class small molecule targeted inhibitor of DNA damage repair enzymes (PARP) with dual Tankyrase inhibitor activity: • Tankyrases are involved in telomere maintenance during tumor cell division and are active in the Wnt signaling pathway in tumor cells. • Dual inhibition of PARP & T
Slide 11: Stenoparib: Wnt/beta-catenin pathway modulation
11 Allarity Therapeutics 1. Lou Stancato et al: AACR Poster 2026. Stenoparib: Wnt / - catenin pathway modulation Active (non - phosphorylated) Beta Catenin TCF - LEF Promoter Reporter Activity (Colo320 72 hrs )
Slide 12: Stenoparib monotherapy twice daily in DRP positive patients: extended survival
12 Stenoparib monotherapy twice daily in DRP positive patients: Extended survival in platinum resistant ovarian cancer patients Allarity Therapeutics 0 0 0 0 0 1 1 1 1 0 0 0 1 1 0 ECOG Platinum refract Platinum resist Platinum sensit Prior Elahere Prior PARP Arrows indicate subjects A live at last c
Slide 13: Overall survival in 3rd line+ ovarian cancer treated with Stenoparib Monotherapy
13 Overall survival in 3 rd line+ ovarian cancer treated with Stenoparib Monotherapy Allarity Therapeutics 0 5 10 15 20 25 30 0 . 0 0 . 2 0 . 4 0 . 6 0 . 8 1 . 0 Months O v e r a l l S u r v i v a l m edianOS = 22 months 1. AACR Annual Meeting 2026, San Diego.
Slide 14: The Stenoparib-DRP identifies patients with extended overall survival
14 The Stenoparib - DRP identifies patients with extended overall survival Allarity Therapeutics Patients were selected for trial based on DRP score cutoff 50. DRP score cutoff 80 further stratifies patients: Median OS below 80 (N= 2) = 3 mo M edian OS above 80 (N=13) = 24 mo HR = 0.13, P=0.04 0 5 1
Slide 15: New Protocol for Phase 2 Trial in Ovarian Cancer
15 New Protocol for Phase 2 Trial in Ovarian Cancer: Stenoparib Monotherapy in Platinum Resistant or Ineligible Ovarian Cancer Allarity Therapeutics Corporate Overview Objective: Solidify Dose for Pivotal Trial, Establish Cut - point for DRP Pre - selection in Pivotal Trial Patients with Platinum re
Slide 16: Backup slides
Backup slides gi illarity
Slide 17: Stenoparib Shows Low Myelotoxicity
17 Stenoparib Shows Low Myelotoxicity Allarity Therapeutics Stenoparib QD+BID (N=42) 1 Approved PARPi ex. Niraparib QD (N=463) 2 Grade 3 - 4 Grade 1 - 4 0% 2% Neutropenia 7% 21% Anemia 0% 0% Thrombocytopenia Grade 3 - 4 Grade 1 - 4 13% 20% Neutropenia 27% 51% Anemia 28% 52% Thrombocytopenia Safety P
Slide 18: Stenoparib BID compared to the PARP selective Saruparib
18 2025 Stenoparib BID compared to the PARP 1 selective Saruparib currently under development by AstraZeneca Allarity Therapeutics Stenoparib BID (N=15) 1 PARP1 selective Saruparib QD (N=141) 2 Grade 3 - 4 (95% CI) Grade 1 - 4 (95% CI) 0% (0 - 25) 7% (0 - 34) Neutropenia 20% (5 - 49) 20% (5 - 49) An
Slide 19: VA sponsored Phase 2: Stenoparib + TMZ in recurrent SCLC
19 Allarity Therapeutics Corporate Overview VA sponsored Phase 2: Stenoparib + TMZ in recurrent SCLC Fully funded, Allarity provides drug product. 11 VA sites opened January 2026 Original clinical trial schema of niraparib + TMZ » Niraparib was the original PARPi used in design but is being replaced
Slide 20: Allarity's DRP may identify patients most likely to benefit from anti-cancer therapies
20 Allarity Therapeutics • The DRP technology has been successful in identifying patients who may benefit from cancer drugs in a number of distinct indications • DRP has been prospectively used in a trial of LiPlaCis where it was able to enrich for responding patients • DRP has been retrospectively
Slide 21: Thomas Jensen, CEO
Thomas Jensen CEO tjensen@allarity.com allarity.com NASDAQ: ALLR
Slide 22: Publications of Clinical/Method Validation for Drug-Specific DRP
Publications of Clinical/Method Validation for Drug-Specific DRP® 14. iG. Chen J, et al. A 71-gene signature of TRAIL sensitivity in cancer cells. (October 25, 2011); Mol Cancer Ther, 10.1158/1535-7163. Wang W, et al. Independent validation of a model using celll line chemosensitivity to predict res
Allarity Therapeutics — Investor Presentation (May 2026) on 6ix